Investors of Immutep Limited Face Securities Fraud Class Action Opportunity

Immutep Limited Securities Fraud Class Action Lawsuit

Los Angeles, June 8, 2026 – The Schall Law Firm, a leading litigation firm advocating for shareholder rights, has initiated a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged violations of securities laws. This lawsuit specifically addresses claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 along with SEC Rule 10b-5.

If you are an investor who purchased Immutep's securities between March 24, 2025, and March 12, 2026, it's essential to be aware of this development. The firm is calling on individuals affected to reach out before the forthcoming deadline on July 6, 2026. Participation in this case could be crucial for recovering any financial losses sustained during the alleged misrepresentations by the company.

The allegations made in the complaint highlight serious concerns regarding the integrity of communications from Immutep Limited. As stated, the company seemingly misrepresented the outcomes of its significant TACTI-004 trial concerning the drug eftilagimod alfa (referred to as 'efti'). On January 30, 2026, in a Form-K filing with the SEC, Immutep asserted that the trial was showing 'strong operational progress'. However, behind this positivity, the company was reportedly aware that the trial was not meeting its primary efficacy endpoints and would ultimately fail.

The Schall Law Firm emphasizes that such misleading information has led to significant consequences for investors. When the truth about the trial's failure was revealed to the market, many shareholders reportedly suffered substantial losses. In this lawsuit, the firm seeks to ensure that these investors receive justice and are compensated for their financial setbacks.

If you believe you are eligible to join this lawsuit, you are highly encouraged to reach out to Brian Schall, managing partner of the Schall Law Firm located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or contact them by phone at 310-301-3335. You also have the option to interact with the firm’s representatives via their website or email, ensuring your legal rights are adequately represented and protected at no cost.

While the class has not yet been certified, joining the lawsuit is critical for potential recovery. Investors who opt to remain passive may miss the opportunity to seek restitution and would be classified as absent class members. The Schall Law Firm pledges to fight for shareholders' rights and is prepared to advocate vigorously in the interest of affected investors worldwide.

This class action serves as a significant reminder of the importance of transparency and honesty in corporate communications and the vital role that regulatory bodies play in protecting investors from financial fraud. With ongoing legal proceedings, the outcome of this lawsuit could set a precedent in the realm of securities litigation, especially within the healthcare and biotechnology sectors.

In light of these developments, individuals with investments in Immutep Limited should take immediate action to understand their legal standing and options. Should you fall under the criteria established, becoming actively involved can either help recover lost investments or contribute to holding corporations accountable for negligent practices.

Stay tuned for further updates on this case and similar legal battles that could affect investor rights and corporate governance in the broader marketplace.